102 related articles for article (PubMed ID: 20009920)
1. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
[TBL] [Abstract][Full Text] [Related]
3. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
[TBL] [Abstract][Full Text] [Related]
4. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
McMahon MA; Siliciano JD; Lai J; Liu JO; Stivers JT; Siliciano RF; Kohli RM
J Biol Chem; 2008 Nov; 283(46):31289-93. PubMed ID: 18818198
[TBL] [Abstract][Full Text] [Related]
5. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
6. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir.
Rossi L; Brandi G; Schiavano GF; Balestra E; Millo E; Scarfi S; Damonte G; Gasparini A; Magnani M; Perno CF; Benatti U; De Flora A
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):435-44. PubMed ID: 9546803
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.
Henao-Martínez AF; Weinberg A; Waldman WJ; Levi ME
J Clin Virol; 2012 Jul; 54(3):276-8. PubMed ID: 22465339
[TBL] [Abstract][Full Text] [Related]
9. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
Arinze F; Shaver A; Raffanti S
Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
[TBL] [Abstract][Full Text] [Related]
10. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
[TBL] [Abstract][Full Text] [Related]
11. Detection of a novel mutation conferring acyclovir resistance and consecutive treatment failure in an HIV-positive patient with recurrent HSV-2 infection.
Schleenvoigt BT; Pletz MW; Deinhardt-Emmer S; Sauerbrei A
J Glob Antimicrob Resist; 2018 Mar; 12():20. PubMed ID: 29179992
[No Abstract] [Full Text] [Related]
12. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient.
Pardeiro M; Cuenca-Estrella M; Fernández-Clúa MA; Santos-O'Connor F; Tabarés E; Gadea I
J Med Virol; 2004 May; 73(1):60-4. PubMed ID: 15042649
[TBL] [Abstract][Full Text] [Related]
14. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
Kuritzkes DR
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
[No Abstract] [Full Text] [Related]
15. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
[TBL] [Abstract][Full Text] [Related]
16. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.
Tchesnokov EP; Obikhod A; Massud I; Lisco A; Vanpouille C; Brichacek B; Balzarini J; McGuigan C; Derudas M; Margolis L; Schinazi RF; Götte M
J Biol Chem; 2009 Aug; 284(32):21496-504. PubMed ID: 19509419
[TBL] [Abstract][Full Text] [Related]
18. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
19. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
